MUC1 and COVID-19: In the same study, the prevalence rate of pulmonary fibrosis in severe COVID-19 cases was much higher than in non-severe cases, indicating that high KL-6 levels in serum in severe COVID-19 cases may be a useful biomarker for predicting lung fibrosis [33].